PA21 (2.5 g tablet containing 500 mg iron)
Sponsors
Vifor Pharma
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Phase 3
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
CompletedNCT01324128
Start: 2011-03-31End: 2012-10-31Updated: 2014-04-24
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
CompletedNCT01464190
Start: 2011-09-30End: 2013-04-30Updated: 2014-04-01